COVID-19 in patients with cancer: managing a pandemic within a pandemic

por Horn, Leora, Garassino, Marina
Publicado 2020

Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer

por Broggini, Massimo, Garassino, Marina Chiara, Damia, Giovanna
Publicado 2013

2020s Heroes Are Not Fearless: The Impact of the COVID-19 Pandemic on Wellbeing and Emotions of Italian Health Care Workers During Italy Phase 1

por Marton, Giulia, Vergani, Laura, Mazzocco, Ketti, Garassino, Marina Chiara, Pravettoni, Gabriella
Publicado 2020

Myeloid cell heterogeneity in lung cancer: implication for immunotherapy

por Sangaletti, Sabina, Ferrara, Roberto, Tripodo, Claudio, Garassino, Marina Chiara, Colombo, Mario Paolo
Publicado 2021

Regulation of PD-L1 Expression by NF-κB in Cancer

por Antonangeli, Fabrizio, Natalini, Ambra, Garassino, Marina Chiara, Sica, Antonio, Santoni, Angela, Di Rosa, Francesca
Publicado 2020

Severity of COVID-19 in patients with lung cancer: evidence and challenges

por Passaro, Antonio, Bestvina, Christine, Velez Velez, Maria, Garassino, Marina Chiara, Garon, Edward, Peters, Solange
Publicado 2021

Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations

por Ferrara, Roberto, Signorelli, Diego, Proto, Claudia, Prelaj, Arsela, Garassino, Marina Chiara, Lo Russo, Giuseppe
Publicado 2021

Is hyperprogressive disease a specific phenomenom of immunotherapy?

por Brambilla, Marta, Russo, Giuseppe Lo, Ferrara, Roberto, Manglaviti, Sara, Garassino, Marina Chiara, Occhipinti, Mario
Publicado 2020

Targeted Toxicities: Protocols for Monitoring the Adverse Events of Targeted Therapies Used in the Treatment of Non-Small Cell Lung Cancer

por Hines, Jacobi B., Bowar, Benjamin, Levine, Emma, Esposito, Alessandra, Garassino, Marina C., Bestvina, Christine M.
Publicado 2023

AB012. Automated histologic subtyping of thymic epithelial tumors with deep learning

por Dolezal, James M., Guo, Wenji, Bestvina, Christine, Vokes, Everett, Donington, Jessica, Husain, Aliya, Garassino, Marina Chiara
Publicado 2022

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib

por Caiola, Elisa, Frapolli, Roberta, Tomanelli, Michele, Valerio, Rossana, Iezzi, Alice, Garassino, Marina C., Broggini, Massimo, Marabese, Mirko
Publicado 2018

Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multileve...

por Caiola, Elisa, Falcetta, Francesca, Giordano, Silvia, Marabese, Mirko, Garassino, Marina C., Broggini, Massimo, Pastorelli, Roberta, Brunelli, Laura
Publicado 2018

MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review

por Lo Russo, Giuseppe, Tessari, Anna, Capece, Marina, Galli, Giulia, de Braud, Filippo, Garassino, Marina Chiara, Palmieri, Dario
Publicado 2018

Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment

por Borzi, Cristina, Galli, Giulia, Ganzinelli, Monica, Signorelli, Diego, Vernieri, Claudio, Garassino, Marina Chiara, Sozzi, Gabriella, Moro, Massimo
Publicado 2020

The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs

por Rulli, Eliana, Guffanti, Federica, Caiola, Elisa, Ganzinelli, Monica, Damia, Giovanna, Garassino, Marina C., Piva, Sheila, Ceppi, Lorenzo, Broggini, Massimo, Marabese, Mirko
Publicado 2016

Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations

por Garassino, Marina C., Oskar, Sabine, Arunachalam, Ashwini, Zu, Ke, Kao, Yu-Han, Chen, Cai, Meng, Weilin, Pietanza, M. Catherine, Zhao, Bin, Aggarwal, Himani
Publicado 2023

Maintenance therapy in NSCLC: why? To whom? Which agent?

por Novello, Silvia, Milella, Michele, Tiseo, Marcello, Banna, Giuseppe, Cortinovis, Diego, Di Maio, Massimo, Garassino, Marina, Maione, Paolo, Martelli, Olga, Vavalà, Tiziana, Bria, Emilio
Publicado 2011

Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know

por Camelliti, Simone, Le Noci, Valentino, Bianchi, Francesca, Moscheni, Claudia, Arnaboldi, Francesca, Gagliano, Nicoletta, Balsari, Andrea, Garassino, Marina Chiara, Tagliabue, Elda, Sfondrini, Lucia, Sommariva, Michele
Publicado 2020

What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?

por Cameron, Robert B., Hines, Jacobi B., Torri, Valter, Porcu, Luca, Donington, Jessica, Bestvina, Christine M., Vokes, Everett, Dolezal, James M., Esposito, Alessandra, Garassino, Marina C.
Publicado 2023

Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of...

por Rizvi, Naiyer, Barlesi, Fabrice, Brahmer, Julie, Felip, Enriqueta, Forde, Patrick, Garassino, Marina, Goldberg, Sarah, Vansteenkiste, Johan, Jarkowski, Anthony, McIntosh, Stuart, Zhao, Luping, Antonia, Scott
Publicado 2015